Advances in the Therapy of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in 2025

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis affecting small to medium-sized vessels, characterized by asthma, eosinophilia, and inflammation. Recent advances in the understanding of EGPA pathogenesis have facilitated the development of targeted therapies, particularly biologics, aimed at improving disease control and reducing treatment-associated toxicity. This review discusses the current therapeutic landscape for EGPA in 2025, highlighting key clinical trials, real-world data, and future directions.